Skip to main content
Top
Published in: Tumor Biology 7/2015

01-07-2015 | Research Article

MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration

Published in: Tumor Biology | Issue 7/2015

Login to get access

Abstract

The non-coding microRNAs (miRNAs) have tissue- and disease-specific expression patterns. Dysregulation of miRNAs has been associated with initiation and progression of oncogenesis in humans. The abnormal expression of CDC25B phosphatases detected in a number of tumors implies that their dysregulation is involved in malignant transformation. Using miRNA target prediction software, we found that miR-211 could target the 3′UTR sequence of CDC25B. To shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues. MiR-211 is significantly downregulated in breast cancer. MiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231. Luciferase expression from a reporter vector containing the CDC25B −3′UTR was decreased when this construct was transfected with miR-211. The over-expression of miR-211 suppressed the endogenous CDC25B protein level in TNBC cells. For the first time, we demonstrate that miRNA-211 is a direct negative regulator of CDC25B expression in TNBC cells, alters other related target proteins CCNB1 and FOXM1, and then inhibits breast cancer cells growth, migration, and invasion and lead G2/M arrest. The transcriptional loss of miR-211 and the resultant increase in CDC25B expression facilitate increased genomic instability at an early stage of tumor development.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
go back to reference Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.CrossRefPubMed Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.CrossRefPubMed
3.
4.
go back to reference De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (tnbc): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80–6.CrossRefPubMed De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (tnbc): current options and future perspectives. Cancer Treat Rev. 2010;36 Suppl 3:S80–6.CrossRefPubMed
6.
10.
go back to reference Luo EC, Chang YC, Sher YP, Huang WY, Chuang LL, Chiu YC, et al. Microrna-769-3p down-regulates ndrg1 and enhances apoptosis in mcf-7 cells during reoxygenation. Sci Rep. 2014;4:5908.PubMedPubMedCentral Luo EC, Chang YC, Sher YP, Huang WY, Chuang LL, Chiu YC, et al. Microrna-769-3p down-regulates ndrg1 and enhances apoptosis in mcf-7 cells during reoxygenation. Sci Rep. 2014;4:5908.PubMedPubMedCentral
11.
go back to reference Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–90.PubMedPubMedCentral Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–90.PubMedPubMedCentral
12.
go back to reference Boutros R, Dozier C, Ducommun B. The when and wheres of cdc25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed Boutros R, Dozier C, Ducommun B. The when and wheres of cdc25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed
13.
go back to reference Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed Boutros R, Lobjois V, Ducommun B. Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed
14.
go back to reference Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin a/cdk2 is blocked in g2 phase arrested cells independently of atm/atr. Oncogene. 2001;20:921–32.CrossRefPubMed Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B. Cdc25-dependent activation of cyclin a/cdk2 is blocked in g2 phase arrested cells independently of atm/atr. Oncogene. 2001;20:921–32.CrossRefPubMed
15.
go back to reference Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25b phosphatase in mitosis triggers centrosomal microtubule nucleation in hela cells. J Cell Sci. 1996;109(Pt 5):1081–93.PubMed Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25b phosphatase in mitosis triggers centrosomal microtubule nucleation in hela cells. J Cell Sci. 1996;109(Pt 5):1081–93.PubMed
16.
go back to reference Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25b and cdc25c differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146:573–84.CrossRefPubMedPubMedCentral Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25b and cdc25c differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999;146:573–84.CrossRefPubMedPubMedCentral
17.
go back to reference Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of cdc25b functions to coordinate mitotic events. Cell Cycle. 2006;5:2543–7.CrossRefPubMed Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of cdc25b functions to coordinate mitotic events. Cell Cycle. 2006;5:2543–7.CrossRefPubMed
18.
go back to reference van Vugt MA, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a g2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799–811.CrossRefPubMed van Vugt MA, Bras A, Medema RH. Polo-like kinase-1 controls recovery from a g2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799–811.CrossRefPubMed
19.
go back to reference Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of cdc25b in cancer cells by releasing sp1 from the promoter. Oncogene. 2013;32:5123–8.CrossRefPubMed Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of cdc25b in cancer cells by releasing sp1 from the promoter. Oncogene. 2013;32:5123–8.CrossRefPubMed
20.
go back to reference Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, et al. Rsk promotes g2/m transition through activating phosphorylation of cdc25a and cdc25b. Oncogene. 2014;33:2385–94.CrossRefPubMed Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, et al. Rsk promotes g2/m transition through activating phosphorylation of cdc25a and cdc25b. Oncogene. 2014;33:2385–94.CrossRefPubMed
21.
go back to reference Lyons J, Bastian BC, McCormick F. Mc1r and camp signaling inhibit cdc25b activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013;110:13845–50.CrossRefPubMedPubMedCentral Lyons J, Bastian BC, McCormick F. Mc1r and camp signaling inhibit cdc25b activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013;110:13845–50.CrossRefPubMedPubMedCentral
22.
go back to reference Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. Microrna-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting cdc25b. Lab Invest. 2011;91:1472–9.CrossRefPubMed Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. Microrna-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting cdc25b. Lab Invest. 2011;91:1472–9.CrossRefPubMed
23.
27.
go back to reference Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMed Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMed
28.
go back to reference Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of mitf-induced microrna-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of mitf-induced microrna-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral
29.
go back to reference Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. Microrna-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor chd5. PLoS One. 2012;7:e29750.CrossRefPubMedPubMedCentral Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. Microrna-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor chd5. PLoS One. 2012;7:e29750.CrossRefPubMedPubMedCentral
30.
go back to reference Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microrna-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.PubMed Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microrna-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.PubMed
31.
go back to reference Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.CrossRefPubMed Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.CrossRefPubMed
32.
go back to reference Zhang Z, Zhang G, Kong C. High expression of cdc25b and low expression of 14-3-3sigma is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 2014;35:2503–12.CrossRefPubMed Zhang Z, Zhang G, Kong C. High expression of cdc25b and low expression of 14-3-3sigma is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 2014;35:2503–12.CrossRefPubMed
33.
go back to reference Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of cdc25b in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13:931–5.CrossRefPubMed Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of cdc25b in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev. 2012;13:931–5.CrossRefPubMed
34.
35.
go back to reference Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. Mir-379 regulates cyclin b1 expression and is decreased in breast cancer. PLoS One. 2013;8:e68753.CrossRefPubMedPubMedCentral Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. Mir-379 regulates cyclin b1 expression and is decreased in breast cancer. PLoS One. 2013;8:e68753.CrossRefPubMedPubMedCentral
36.
go back to reference Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. Grk2 negatively regulates igf-1r signaling pathway and cyclins’ expression in hepg2 cells. J Cell Physiol. 2013;228:1897–901.CrossRefPubMed Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. Grk2 negatively regulates igf-1r signaling pathway and cyclins’ expression in hepg2 cells. J Cell Physiol. 2013;228:1897–901.CrossRefPubMed
38.
go back to reference Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, et al. Foxm1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.CrossRefPubMed Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, et al. Foxm1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 2012;114:755–62.CrossRefPubMed
39.
go back to reference Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. Foxm1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2010;122:337–46.CrossRefPubMed Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. Foxm1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2010;122:337–46.CrossRefPubMed
Metadata
Title
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration
Publication date
01-07-2015
Published in
Tumor Biology / Issue 7/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3151-6

Other articles of this Issue 7/2015

Tumor Biology 7/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine